These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34034128)

  • 1. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.
    Li X; Dou J; You Q; Jiang Z
    Eur J Med Chem; 2021 Aug; 220():113539. PubMed ID: 34034128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
    Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
    J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1.
    Lou J; Zhou Q; Lyu X; Cen X; Liu C; Yan Z; Li Y; Tang H; Liu Q; Ding J; Lu Y; Huang H; Xie H; Zhao Y
    J Med Chem; 2024 Jul; 67(13):10795-10830. PubMed ID: 38913996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
    Ahn IE; Davids MS
    Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J
    Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
    Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
    Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
    [No Abstract]   [Full Text] [Related]  

  • 9. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
    Cang S; Iragavarapu C; Savooji J; Song Y; Liu D
    J Hematol Oncol; 2015 Nov; 8():129. PubMed ID: 26589495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Ng SY; Davids MS
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax in the treatment of chronic lymphocytic leukemia.
    Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW; Huang D
    Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-199 for chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
    [No Abstract]   [Full Text] [Related]  

  • 14. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent.
    Žigart N; Časar Z
    Expert Opin Ther Pat; 2019 Jul; 29(7):487-496. PubMed ID: 31154862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutics targeting Bcl-2 in hematological malignancies.
    Ruefli-Brasse A; Reed JC
    Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax: Targeting BCL2 in Hematological Cancers.
    Scheffold A; Jebaraj BMC; Stilgenbauer S
    Recent Results Cancer Res; 2018; 212():215-242. PubMed ID: 30069633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Covalent Molecular Inhibitor of Anti-apoptotic BFL-1 by Disulfide Tethering.
    Harvey EP; Hauseman ZJ; Cohen DT; Rettenmaier TJ; Lee S; Huhn AJ; Wales TE; Seo HS; Luccarelli J; Newman CE; Guerra RM; Bird GH; Dhe-Paganon S; Engen JR; Wells JA; Walensky LD
    Cell Chem Biol; 2020 Jun; 27(6):647-656.e6. PubMed ID: 32413285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Lampson BL; Davids MS
    Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.